Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has been effective faithfully but unsuccessfully to produce an one-time therapy, variously called Pro 140, leronlimab, as well as Vyrologix.

In development of this treatment, CytoDyn has cast its net wide and far both geographically and in phrases of potential indications.

CytoDyn’s inventories of leronlimab are building up, whether they will actually be being used is actually an open question.

While CYDY  happens to be dawdling, market opportunities for leronlimab as being a combination therapy in the curing of multi-drug-resistant HIV are actually closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale made of the past several shares of mine. My 1st CytoDyn article, “CytoDyn: What to be able to Do When It’s Too Good to be able to Be True?”, set out what follows prediction:

Instead I expect it to turn into a serial disappointer. CEO Pourhassan presented such a very promotional picture in the Uptick Newswire job interview that I came away with a poor impression of the business.

Irony of irony, my bad opinion of the company has grown steadily, yet the disappointment hasn’t been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > six bagger at the moment still disappoints? Therein is the story; permit me to explain.

CytoDyn acquired its much storied treatment (which I shall refer to as leronlimab) returned in 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for your therapy and prevention of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti-viral activity in HIV infected subjects. Today’s transaction of $3.5 million transfers ownership of the know-how and also connected intellectual property from Progenics to CytoDyn, and also roughly 25 million mg of bulk drug substance…. milestone payments after commencement of a stage III clinical trial ($1.5 zillion) and also the first brand new drug program endorsement ($5 million), and even royalty payments of 5 % of net sales after commercialization.

Since that point in time, CytoDyn’s leading nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition right into a springboard for CytoDyn to purchase a sector cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with many therapies and many indications, it’s this individual remedy in addition to a “broad pipeline of indications” because it puts it. I call some pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a likely beneficial therapy in dozens of indications.

Its opening banner on the website of its (below) shows an active business with diverse interests albeit centered on leronlimab, multiple illness types, multiple publications and multiple delivering presentations.

Can all of it be smoke and mirrors? That is a question I’ve been asking myself through the very start of the interest of mine in this business. Judging with the multiples of thousands of several commentary on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I’m a lot from alone in this question.

CytoDyn is a traditional battleground, or maybe some could say cult inventory. Its adherents are fiercely shielding of its prospects, quick to label any bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *